Literature DB >> 1721045

Proctor Lecture. Experimental allergic uveitis. Investigations of retinal autoimmunity and the immunopathologic responses evoked.

W B Wacker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721045

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


× No keyword cloud information.
  6 in total

Review 1.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

Review 2.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

3.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

4.  Animal model for uveitic glaucoma.

Authors:  A Mermoud; G Baerveldt; D S Mickler; G S Wu; N A Rao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

5.  Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier.

Authors:  David A Copland; Jian Liu; Lauren P Schewitz-Bowers; Volker Brinkmann; Karen Anderson; Lindsay B Nicholson; Andrew D Dick
Journal:  Am J Pathol       Date:  2011-11-24       Impact factor: 4.307

6.  Good news-bad news: the Yin and Yang of immune privilege in the eye.

Authors:  John V Forrester; Heping Xu
Journal:  Front Immunol       Date:  2012-11-27       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.